Percutaneous Implantable Cardiovascular Support (PICS) System

PICS

A Novel Minimally-invasive Cardiovascular Support Medical Device Company

Background

NHSIL has partnered with a London University to develop a novel minimally invasive Percutaneous Implantable Cardiovascular Support System (PICS) that would change the lives of hundreds of thousands of patients and their families following congestive heart failure (CHF). The novel technology around PICS would reduce the risks associated with current heart support devices used following CHF.

Problem

Left Ventricular Assist Devices (LVADs) have been available for end stage (class IV) heart failure for several decades. Over 100,000 patients are indicated for their use in the US alone. However, the market uptake for LVADs has been slow due to: cost - current devices alone cost $75,000 with a reimbursement price of $136,000, increased risk of stroke, infection and sepsis (requiring prophylactic administration of broad spectrum antibiotics), highly invasive surgery, antiplatelet therapy requirements and haemolysis due to fluid shear.

Solution

PICS is a novel concept which brings together the positive aspects of current LVADs whilst tackling their problems and associated stigma. The PICS device will be small enough to be implanted through a mini thoracotmy - an intercostal incision 10cm long which does not require a sternotomy. The system will also have a component which can be replaced percutaneously negating the need for further redo surgery should the device fail or wear out.

Market Potential

The market potential for this device is several billion dollars per annum with the reduced risk of stroke and infection. With its easier implementation and lower device and reimbursement price, PICS is expected to have a strong market position. The less invasive nature of the device will also open up the use of LVADs to a currently untapped market.

Status

NHSIL provided feasibility funding for the successful development and testing of a benchtop model of a percutaneous, minimally invasive system. Further development funding has been provided for further component design and refinement prior to a pre-clinical device being constructed and tested.

Further information

Please contact David Chilvers, Chief Executive, NHS Innovations London Ltd.